However, sodium glucose transporter type 2 (SGLT2) inhibitors not only cause glucosuria and improve diabetic compensation, but also decrease the risk of chronic kidney disease (CKD) progression [1,2,3], decrease the risk of cardiovascular events [3,4,5,6,7], and even lower all-cause mortality in treated patients [2,4,6,8]. Here, SLC5A2 is linked to chronic kidney disease.